ISDA

Entry Detail

PDB ID:

2ANK

Keywords:

HYDROLASE/HYDROLASE INHIBITOR

Title:

orally active thrombin inhibitors in complex with thrombin and an exosite decapeptide

Biological Source:

Source Organism:

Synthetic, Homo sapiens

PDB Version:

Deposition Date:

2005-08-11

Release Date:

2006-11-14

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.46 Å

R-Value Free:

0.21

R-Value Work:

0.17

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Thrombin heavy chain
Chain IDs:A (auth: H)
Chain Length:259
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P00734 Pfam ID:PF00089, PF09396 EC:3.4.21.5

Protein Blast

Polymer Type:polypeptide(L)
Description:Thrombin light chain
Chain IDs:B (auth: L)
Chain Length:34
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P00734 Pfam ID:PF00089, PF09396 EC:3.4.21.5

Polymer Type:polypeptide(L)
Description:synthetic peptide
Chain IDs:C (auth: P)
Chain Length:11
Number of Molecules:1
Biological Source:Synthetic

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details
ALC	C	ALA	2-AMINO-3-CYCLOHEXYL-PROPIONIC ACID
HYP	C	PRO	4-HYDROXYPROLINE
SMF	C	PHE	4-SULFOMETHYL-L-PHENYLALANINE

Ligand Molecules

N12

Peptide-like Molecules

PRD_000480

Primary Citation

Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety

Lange, U.E.W, Baucke, D, Hornberger, W, Mack, H, Seitz, W, Hoeffken, H.W.Show

BIOORG.MED.CHEM.LETT. 16 2648 2653 (2006)

PMID: 16460939 DOI: 10.1016/j.bmcl.2006.01.046

Abstact

Synthesis and SAR of orally active thrombin inhibitors of the d-Phe-Pro-Arg type with focus on the P2-moiety are described. The unexpected increase in in vitro potency, oral bioavailability, and in vivo activity of inhibitors with dehydroproline as P2-isostere is discussed. Over a period of 24h the antithrombin activity of the most active inhibitors with IC(50)s in the nanomolar range was determined in dogs demonstrating high thrombin inhibitory activity in plasma and an appropriate duration of action after oral administration.

Legend

Protein

Chemical

Disease

Primary Citation of related structures